For the quarter ended September 2025, Health Catalyst (HCAT) reported revenue of $76.32 million, representing no change compared to the same period last year. EPS came in at $0.06, compared to $0.07 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $75.08 million, representing a surprise of +1.66%. The company delivered an EPS surprise of +20%, with the consensus EPS estimate being $0.05.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Health Catalyst performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:View all Key Company Metrics for Health Catalyst here>>>
Shares of Health Catalyst have returned +6.8% over the past month versus the Zacks S&P 500 composite's +0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| Sep-14 | |
| Sep-14 | |
| Sep-10 | |
| Sep-08 | |
| Aug-31 | |
| Aug-07 | |
| Aug-06 | |
| Aug-06 | |
| Aug-06 | |
| Jul-28 | |
| Jun-16 | |
| Jun-04 | |
| Jun-04 | |
| May-12 | |
| May-11 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite